DOT1L inhibition has been suggested as an antitumor strategy for the development of active immunotherapies using tumor antigen‐loaded DCs, but exploration of this avenue has become stagnant (Stein and Tallman, 2015; Vlaming and van Leeuwen, 2016; Xu and Cao, 2011). This evidence concerns the gene DOT1L and neoplasm.